Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InSync in Circulation

This article was originally published in The Gray Sheet

Executive Summary

Medtronic Impedance Diagnostics in Heart Failure Trial results demonstrating the efficacy of OptiVol fluid status monitoring technology appear in Aug. 9 edition of Circulation, the Journal of the American Heart Association. Featured on Medtronic's InSync Sentry cardiac resynchronization defibrillator, OptiVol is "shown to provide a warning of fluid accumulation in some patients an average of 15 days before heart failure symptoms appeared and 18 days before hospital admission," according to an Aug. 9 release...

You may also be interested in...



Medtronic’s Cardiac Disease Management Offerings Seek To Grow HF Market

Medtronic believes that its foray into cardiac disease management with the Chronicle implantable hemodynamic monitor will differentiate its devices from competitors Guidant and St. Jude

Warning Letter Roundup & Recap – 26 January 2021

No device-related warning letters were released by the US FDA the week of 26 January.

EU Crunch Time For Two Drugs That Lost Their Fast-Track Status

Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel